In addition, the CAR T cell responses to adult glioma (with high EphA3 expression) were more effective than against a glioma target expressing lower antigen levels, highlighting the importance of target antigen density in patient selection in clinical trial design.41 The gene discussed is EPHA3; the disease is glioma.